MAXIMUM RESULTS Starting at $250/month Targets BOTH GLP-1 and GIP receptors Average 2022% body weight loss (SURMOUNT trial data) Once-weekly subcutaneous injection Stronger insulin sensitivity benefit Often greater appetite suppression Compounded by licensed 503A pharmacy Patients seeking maximum weight loss results, those with insulin resistance or pre-diabetes, or anyone who didn't respond optimally to semaglutide alone
It is whether a licensed provider screened you, ran your labs, sourced the compound responsibly, and adjusted your dose over time
By building this AI infrastructure, Roche aims to do now what patients need next ( [65] ): get safe, effective medicines and diagnostics into hands faster and more efficiently
For broader clinical use, however, these benefits require systematic and well-designed clinical validation (64)
With that popularity comes a wide range of pricing that can be confusing at first glance